Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2010 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ORAVIG

« Back to Dashboard
Oravig is a drug marketed by Bioalliance Pharma and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

The generic ingredient in ORAVIG is miconazole. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole profile page.

Summary for Tradename: ORAVIG

Suppliers: see list1

Pharmacology for Tradename: ORAVIG

Drug ClassAzole Antifungal

Clinical Trials for: ORAVIG

Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Status: Recruiting Condition: Melasma

Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
Status: Completed Condition: HIV Infections

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Status: Completed Condition: Bacterial Vaginosis; Candidiasis; Trichomoniasis

Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans
Status: Completed Condition: Healthy

Antifungal Use in Oncohematological Neutropenic Patients
Status: Completed Condition: Invader Fungal Infection

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
Status: Completed Condition: Tinea Pedis

Antifungal Locks to Treat Fungal-Related Central Line Infections
Status: Recruiting Condition: Central Line Fungal Infections

An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women
Status: Recruiting Condition: Antifungal Drug Adverse Reaction

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
Status: Active, not recruiting Condition: Systemic Fungal Infections

Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Status: Active, not recruiting Condition: Antifungal Therapy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bioalliance Pharma
TABLET; BUCCAL022404-001Apr 16, 2010RXYes6,916,485<disabled>Y<disabled>
Bioalliance Pharma
TABLET; BUCCAL022404-001Apr 16, 2010RXYes7,651,698<disabled><disabled>
Bioalliance Pharma
TABLET; BUCCAL022404-001Apr 16, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn